View by Specialty

Trending

DERM0325AAD_Barbieri _Graphic_01
March 13, 2025
4 min read
Save

FDA issues limited acne product recalls, AAD releases statement on benzoyl peroxide

Inflammatory Bowel Disease News

SPONSORED CONTENT
March 21, 2025
2 min read
Save
Tremfya’s FDA win as fully subcutaneous option for Crohn’s may pave way to eclipse Stelara

Tremfya’s FDA win as fully subcutaneous option for Crohn’s may pave way to eclipse Stelara

The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous induction options for the treatment of moderately to severely active Crohn’s disease, Johnson & Johnson reported.

SPONSORED CONTENT
March 19, 2025
2 min read
Save

Etrasimod can be safely used alongside opioids, antidepressants in ulcerative colitis

Etrasimod can be safely used alongside opioids, antidepressants in ulcerative colitis

Using etrasimod with opioids or antidepressants did not increase risk for serotonin syndrome-associated adverse events among patients with ulcerative colitis, according to a study published in United European Gastroenterology Journal.

SPONSORED CONTENT
March 07, 2025
3 min read
Save

Q&A: Wearable devices may help IBD patients track flares in ‘the comfort of their homes’

Q&A: Wearable devices may help IBD patients track flares in ‘the comfort of their homes’

Physiological metrics captured via wearable devices may help identify and predict flares in inflammatory bowel disease, Robert P. Hirten, MD, told Healio, and could potentially play a role in remote monitoring of disease activity.

Trending

DERM0325AAD_Barbieri _Graphic_01
March 13, 2025
4 min read
Save

FDA issues limited acne product recalls, AAD releases statement on benzoyl peroxide

SPONSORED CONTENT
March 04, 2025
2 min read
Save

First four Stelara biosimilars launch in US; ‘white labeling’ threatens market ‘vibrancy’

First four Stelara biosimilars launch in US; ‘white labeling’ threatens market ‘vibrancy’

Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference product manufacturer, Janssen Pharmaceuticals, which set timelines for their market entries.

SPONSORED CONTENT
February 20, 2025
5 min read
Save

Q&A: ‘Everyone benefits’ from noninvasive, individualized monitoring in pediatric IBD

Q&A: ‘Everyone benefits’ from noninvasive, individualized monitoring in pediatric IBD

SAN FRANCISCO — Noninvasive monitoring methods, such as enterography and ultrasound, are becoming increasingly recognized as essential tools in the management of pediatric patients with inflammatory bowel disease, according to presenters.

SPONSORED CONTENT
February 18, 2025
2 min read
Save

Oral vancomycin may offer ‘viable option’ for IBD-related primary sclerosing cholangitis

Oral vancomycin may offer ‘viable option’ for IBD-related primary sclerosing cholangitis

Oral vancomycin therapy resulted in clinical response in nearly half of patients with inflammatory bowel disease associated with primary sclerosing cholangitis, according to a study published in Therapeutic Advances in Gastroenterology.

SPONSORED CONTENT
February 14, 2025
2 min read
Save

VIVID-2: Omvoh demonstrates ‘continued durability,’ safety in Crohn’s disease at 2 years

VIVID-2: Omvoh demonstrates ‘continued durability,’ safety in Crohn’s disease at 2 years

SAN FRANCISCO — Most patients with moderately to severely active Crohn’s disease who achieved endoscopic response and remission after 52 weeks of Omvoh therapy maintained those results through 104 weeks, according to VIVID-2 study results.

SPONSORED CONTENT
February 13, 2025
2 min read
Save

Stelara, Entyvio have ‘comparable’ cardiovascular safety profiles in older adults with IBD

Stelara, Entyvio have ‘comparable’ cardiovascular safety profiles in older adults with IBD

SAN FRANCISCO — Although Stelara and Entyvio demonstrated similar cardiovascular safety profiles among older patients with inflammatory bowel disease, Stelara was associated with reduced all-cause mortality risk over 3 years, data showed.

SPONSORED CONTENT
February 12, 2025
2 min read
Save

Train support staff to be aware of mental health concerns in IBD to avoid future trauma

Train support staff to be aware of mental health concerns in IBD to avoid future trauma

SAN FRANCISCO — Patients with inflammatory bowel disease remain at higher risk for mental health disorders, but training support staff to recognize the symptoms could be key to preventing further traumatization, noted a presenter here.

SPONSORED CONTENT
February 11, 2025
2 min read
Save

Most patients with IBD ‘still experience significant challenges’ accessing, affording care

Most patients with IBD ‘still experience significant challenges’ accessing, affording care

SAN FRANCISCO — Despite advances in treatment for inflammatory bowel disease, more than 55% of patients report medication delays, mostly due to insurance challenges, and many make financial trade-offs to afford care, survey results showed.

View more
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails